How Chinese Biotech Firms Can Overcome Overseas Financing Challenges: Practical Training Program Offers Solutions
In recent years, China’s biotechnology (Biotech) industry has experienced rapid growth, with a continuous emergence of innovative drugs and cutting-edge technological achievements. However, as domestic market competition intensifies and the capital landscape shifts, an increasing number of companies are turning their attention to overseas markets, seeking leapfrog development through international financing. Nevertheless, in the process of “going global,” Chinese Biotech enterprises commonly face numerous core pain points:
A Systematic Understanding of the End-to-End Process for Overseas FundraisingDeficiency, unsure how to proceed
Despite the significant enhancement in technological capabilities among Chinese biotech firms, there remain notable deficiencies in their understanding of the end-to-end process for overseas financing.From establishing an overseas entity (NewCo) and designing the equity structure to engaging with US dollar funds and completing legal and compliance reviews, every step involves intricate operational details.Many enterprises, lacking experience, often find themselves in the predicament of “crossing the river by feeling the stones,” leading to prolonged financing cycles or even failure.
Frequent Legal and Intellectual Property Issues Affect Financing Progress
Cross-border financing involves complex transnational legal issues, including discrepancies in agreement terms, disputes over intellectual property ownership, and tax compliance.Many enterprises, due to their unfamiliarity with international rules, passively accept unfavorable terms in transactions, and even lose control of core technologies as a result of inadequate intellectual property protection.For example, differences in how the Chinese and U.S. legal systems determine the validity of agreements may lead to contractual disputes; meanwhile, loopholes in patent portfolio strategy could directly trigger cross-border litigation.
Pipeline Design Out of Sync with International Clinical Standards, Going GlobalFinancing Difficulties
USD-denominated funds and multinational pharmaceutical companies (MNCs) employ evaluation criteria for projects that differ significantly from those in the Chinese market.Many enterprises, despite possessing technological advantages, suffer from diminished project appeal due to pipeline designs that fail to align with international clinical standards or a lack of data compliant with overseas regulatory requirements.For example, the FDA and EMA impose far more rigorous requirements on clinical trial design than regulators in China; failure to plan ahead could directly lead to financing failures.
In light of the core challenges and difficulties currently faced by Chinese biotech companies in securing overseas financing, Danhuang Technology (VCBeat), in partnership with Niukou Capital, will host an event in Beijing on March 27, 2025.“2025 Practical Training on Overseas Financing for Chinese Biotech Companies”, this training willInviting NewCo model operators, partners from top-tier USD funds, cross-border legal experts, executives from successfully funded companies, and heads of business development at multinational corporations (MNCs) to share insights on NewCo model selection, bridging knowledge gaps, mitigating legal risks, leveraging pipeline BD and financing experience, and optimizing pipeline design.from dimensions such as, sharePractical Experience and Pitfall Avoidance Guide; Continuously track the overseas financing activities of participating companies, provide timely information consultation and resource matching, and ensure the successful realization of financing.
Training Objectives and Mission
1. Provide a detailed introduction to the entire process of overseas financing, helping Chinese biotech companies systematically master the knowledge and understanding required for international fundraising;
2. Review common legal and intellectual property issues in overseas financing, along with case analyses, to help Chinese biotech companies mitigate legal and compliance risks;
3. Provide practical methodologies for USD fund selection, pipeline optimization, and clinical trial design to enhance the fundraising success rate of Chinese biotech companies;
4. Facilitate in-depth exchanges through case studies and mentorship to help resolve enterprise-specific issues and accelerate the financing process.
Training Overview
Training Name: 2025 Practical Training on Overseas Financing for Chinese Biotech Companies
Training Duration: March 27, 2025
Training Venue: Zone C, Haixing Pharmaceutical Health Innovation Park, Haidian District, Beijing
Organizer: Danhuang Tech (VCBeat), Niukou Capital, Haixinyu Urban Renewal, Haixing Tech
Supporting Organizations: AllBright Law Offices, Shanghai; BiXing Law Firm, Shanghai; China Merchants Bank, Shanghai Branch; PwC
Training Outline
1. Opportunities and Challenges for Biotech Companies in Overseas Financing (NewCo)
(1) Global Biotech Company Financing Overview
(2) Overseas Financing Activities of Chinese Biotech Companies
(3) Sharing Success Stories Under the NewCo Innovation Model
(4) Opportunities and Challenges for Chinese Biotech Companies in Overseas Financing
2. Logical Architecture and Full Practical Process Analysis of the NewCo Model
(1) Strategic Interpretation of NewCo’s Overseas Expansion Model
(2) Building NewCo from Scratch: Strategic Logic and Architectural Design
(3) Comprehensive Analysis of the Practical Implementation Process for the NewCo Model
3、Common Tax Considerations and Optimization for Cross-Border Transactions in the Global Expansion of Life Sciences and Pharmaceutical Enterprises
4. How Chinese Biotech Companies Can Properly Avoid Pitfalls in BD-Driven Global Expansion and Going GlobalLegal Risks of Financing Transactions
(1) Common Forms of Overseas Financing Transactions for Chinese Biotech Companies (NewCo Model, BD Deals)
(2) Differences in the China-U.S. Agreement
(3) Legal Risks in Overseas Financing Transactions for Chinese Biotech Companies
(4) Practical Case Studies: How to Properly Avoid Legal Risks in International Transactions
5. How Chinese Biotech Companies Address Intellectual Property Issues in Cross-Border Transactions
(1) Forms of Intellectual Property Cooperation in Cross-Border Transactions by Chinese Biotech Companies
(2) Common Intellectual Property Issues in Cross-Border Transactions for Chinese Biotech Companies
(3) How Chinese Biotech Companies Can Maximize the Protection of Their Intellectual Property
(4) IP Patent Challenge Strategies for Cross-Border Transactions of Chinese Biotech Companies
6、Sharing Experience in Global Business Operations for Enterprises in the Medical and Elderly Care Industry
(1) Establishment of Offshore Structure
(2) Overseas Account Selection
(3) Overseas Fund Management
(4) Cross-border Financing Methods
7. Practical Experience Shared by NewCo Operators
(1) How I Built NewCo
(2) Key Success Factors for NewCo
(3) How I Climbed Out of the Pitfalls I Encountered
8. Selection Criteria for Investment Projects of USD Funds
(1) Analysis of the Most Popular Sectors/Projects Among USD-Denominated Funds
(2) Specific Process and Criteria for Project Screening by USD Funds
（3）How to Negotiate Partnerships with USD Funds
9. Criteria and Direction for MNC Project Selection
(1) Analysis of the Current Investment Status and Direction of MNCs
(2) Specific Processes and Criteria for MNC Project Screening
(3) How to Negotiate Cooperation with MNCs
10. Clinical Strategies Required for Chinese Biotech Companies to Expand Globally
(1) What kind of clinical data is more favored by overseas investors?
(2) Clinical Protocol Strategy and Design for International Projects
Training Guest
Senior Biotech Industry-Finance Expert and Practitioner
Partner, Button Capital
Personal Profile:
As a renowned expert in industry-finance integration within the life sciences sector, he brings over two decades of experience in the capital markets for innovative biopharmaceuticals. He has spearheaded multiple landmark transactions, including the largest PIPE financing for a domestic biotech company and product business development (BD) deals valued at billions of dollars. During his tenure as Chief Financial Officer (CFO) of I-Mab Biopharma, he led the company’s initial public offering on the NASDAQ and drove its market capitalization from $800 million to $7 billion, ranking it among the top five most valuable next-generation biotech firms in China at the time. He has been repeatedly named Best Healthcare CFO by Institutional Investor (II).
Prior to joining Akeso, he served as Head of Asia Healthcare at Jefferies, a globally renowned boutique investment bank, where he directly facilitated cross-border M&A and equity financing transactions totaling over $10 billion. Before Jefferies, he held the position of Head of Healthcare at top-tier investment banks Deutsche Bank and UBS. He graduated from Harvard Business School with distinction, earning the Baker Scholar honor.
Button Capital
Partner
Personal Profile:
Graduated from Shanghai Jiao Tong University, with 15+ years of experience in the healthcare industry, consulting, and investment banking;
Former Managing Director and Sector Head at iCapital; Board Secretary of 111, Inc., successfully leading its NASDAQ listing in 2018 with a market capitalization of $1 billion; General Manager of the Health Insurance Division at Ping An Group, overseeing business lines in health management, PBM, and supply chain management; Capital Markets Analyst at Deutsche Bank.
PwC China
Partner, Tax and Business Advisory
Personal Profile:
Mr. Yuan Chengfei is a Partner in Tax and Business Consulting at PwC China’s Shanghai office, with 15 years of professional experience.Mr. Yuan is responsible for tax due diligence, the design of holding structures, securing tax incentives upon investment exit, reviewing investment contracts, and negotiating investment terms. He has assisted numerous private enterprises in establishing and restructuring tax frameworks, intangible asset tax planning, employee stock ownership incentive plans, related-party transaction tax planning, compliance reviews for mergers and acquisitions, and tax planning for IPO financing.
Since 2019, Mr. Yuan has served numerous companies in the biopharmaceutical technology sector, providing tax planning and compliance services across various stages of their corporate life cycles. His key clients include the Shanghai Biomedical Fund, Tianjing Biotherapeutics (listed on the NYSE), Genor Biopharma (listed on the HKEX), Relive Biotechnologies, Laekna Therapeutics, bioMérieux, Ipsen Pharma, BeiGene, MicroPort Scientific Corporation, Lixin Biotherapeutics, Qianglian Zhichuang, Zhengxiang Biology, and Yuanhe Medical.
Mr. Yuan obtained a Master’s degree in Corporate Tax Law from Paris Dauphine University (Paris IX) in 2006, as well as dual Master of Laws degrees in International Trade Law from Paris Nanterre University (Paris X) and a Bachelor of Laws degree from Panthéon-Assas University (Paris II).
PwC China
U.S. Tax Partner
Personal Profile:
Ms. Hu Luwen is a Partner in PwC China’s North Region US Tax Advisory Services practice, with over ten years of experience in international and US tax planning and compliance filing. She specializes in providing strategic planning and advisory services to Chinese companies and individuals investing in the United States, as well as advising US companies on their overseas investments. Her expertise encompasses global corporate tax structure planning, mergers and acquisitions advisory, and tax strategies related to repatriation of overseas earnings, transfer pricing, and minimization of withholding taxes.
Ms. Hu Luwen has served clients across a range of industries, including private equity, real estate and funds, insurance, financial services, banking, manufacturing, intellectual property, and high technology. Prior to joining PwC’s Beijing office, she worked at PwC in Los Angeles, United States, where her primary clients comprised Fortune 500 companies, mid-sized enterprises, and high-net-worth individuals.
Ms. Hu Luwen earned her Master of Business Administration (MBA) with a concentration in Accounting/Finance from the University of Arizona. She is a Certified Public Accountant (CPA) licensed in California, a member of the American Institute of Certified Public Accountants (AICPA), and a member of the California Society of Certified Public Accountants (CalCPA).
AllBright Law Offices
Partner
Personal Profile:
Attorney Liu Tingting is a partner at AllBright Law Offices (Shanghai) and serves as [position/title] for the China Biopharmaceutical Industry Innovation and Transformation Alliance (CBIITA Alliance).Deputy Director of the Business Development Special Committee, and successively honored as one of the U45 Influential Young Leaders in the China Biopharmaceutical Industry Chain Innovation List.Recognized as one of the “Top 30 Rising Stars in China’s Legal Profession” by the renowned legal ranking agency Legalband in 2023, and recommended as a key lawyer in the Life Sciences and Healthcare sector in mainland China by The Legal 500, an internationally authoritative legal ranking organization.
Since commencing his legal practice, Attorney Liu has focused on providing cross-border legal services to multinational pharmaceutical and medical device companies, investment institutions, and other clients, covering areas such as cross-border technology licensing and transactions, domestic and overseas investment and mergers and acquisitions, and regulatory compliance.Has assisted numerous renowned pharmaceutical companies, both domestic and international, in executing multiple cross-border business development initiatives for global expansion, including technology licensing deals, NewCo formations, and overseas investments.
Bixing Law Firm
Managing Partner, Lawyer, Patent Attorney, Trademark Agent, Technology Broker
Furthermore, since entering the profession, he has actively conducted intellectual property training, delivering over one hundred training sessions, lectures, and speeches.Honored by the China Trademark Association, Asian Legal Business (ALB), IAM, and LegalOne,Multiple awards conferred by domestic and international organizations, including the Shanghai Intellectual Property Services Industry Association.
Steady Capital
Executive Director
Bayer HealthCare
Director of Development
Dr. Li Siyu graduated from Tsinghua University Peking Union Medical College with a Doctor of Medicine (M.D.) degree in Clinical Medicine and holds a medical practitioner’s license.
Miltenyi Biotec (China)
Clinical Development Manager
Master of Science in Global Health from Duke University; currently Head of Clinical Development at Miltenyi Biotec (China), focusing on clinical translation and application promotion in the field of cell and gene therapy. He has extensive experience in the international biopharmaceutical industry and is dedicated to advancing precision medicine and the clinical practice of cutting-edge biotechnologies.
In addition, Mr. Hong Jiayang serves as the Chairman of the China-US Youth Pharmaceutical and Health Alliance, where he actively builds international platforms for academic and industrial exchange to foster cooperation and innovation between China and the United States in the fields of life sciences and pharmaceutical health. He also serves as a career mentor at Duke Kunshan University, dedicated to cultivating the next generation of professional talent in the biomedical sector.
Training Agenda
Training Registration
Scan the QR code above to register
CNY 1,999 per person (early-bird price: CNY 1,699 per person if registered before March 21); group rate for three participants: CNY 1,499 per person. All fees include lunch and a networking dinner.Note: No refunds will be issued within 3 days prior to the event.If you are interested in or have questions about overseas financing, please contact Huimin, the Financing Assistant:
Phone: 15111945514 (WeChat)